+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are studying the effects and safety of different doses of the investigational drug NNC0662-0419 in adults living with type 2 diabetes. This study compares NNC0662-0419 to semaglutide, an approved treatment for type 2 diabetes, and a placebo. The purpose is to find out if NNC0662-0419 is effective and safe for treating this condition. Participants will receive one of the three treatments NNC0662-0419, semaglutide, or placebo, all given as weekly injections under the skin. The dose of NNC0662-0419 will be gradually increased over time. The study uses a randomized design where the treatment assignment is by chance, and both participants and researchers do not know the group assignments. Throughout the study, participants will attend visits and undergo assessments at various weeks up to week 48. Researchers will measure blood sugar control using glycated hemoglobin HbA1c at weeks 16, 28, and 40, as well as body weight, blood glucose levels, cholesterol, kidney function, and other health markers. Safety will be monitored by recording any adverse events. The total study participation will last several months with regular monitoring.

Age: 18Years - 75YearsAll GendersPhase 2
63 locations
S

Actively Recruiting

Researchers are evaluating the safety and effectiveness of NNC0487-0111 for treating adults with excess body weight and type 2 diabetes. The study compares four different doses of NNC0487-0111 with a placebo, which contains no active medicine. Participants receive these treatments as weekly injections under the skin, and their group assignment is decided randomly. Participants are assigned to one of five groups four groups receive different dose levels of NNC0487-0111, and one group receives a placebo. All participants also follow a reduced-calorie diet and increase their physical activity. The injections are administered once weekly using a pre-filled pen injector to the thigh, abdomen, or upper arm. Treatment continues for 84 weeks, with ongoing monitoring. Throughout the study, participants will have their body weight, waist circumference, blood sugar control HbA1c, blood pressure, cholesterol levels, and quality of life assessed at the start and at week 84. Safety is monitored by tracking adverse events and episodes of low blood sugar up to week 88. The study lasts for about 84 weeks of treatment plus safety follow-up, and participants may undergo laboratory tests and physical exams during this time.

Age: 18Years +All GendersPhase 3
74 locations